Skip to content
  • Sunday, 26 July 2026
  • 3:41 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Rethinking Evidence Generation for Ultra-Rare Diseases
Laboratory Automation & Robotics

Rethinking Evidence Generation for Ultra-Rare Diseases

Lana Keisha May 16, 2026 0

The landscape of drug development for ultra-rare diseases is undergoing a significant transformation, driven by the U.S. Food and Drug…

Read More
Microbiology & Immunology

TWiV 1292: Clinical Update with Dr. Daniel Griffin Examines Public Health Decline, Vaccine Policy Shifts, and Resurgent Infectious Diseases

Lina Irawan May 11, 2026 0

In a recent clinical update on the "This Week in Virology" (TWiV) podcast, Dr. Daniel Griffin and host Vincent Racaniello…

Read More
Laboratory Automation & Robotics

Rethinking evidence generation for ultra-rare diseases

Lana Keisha May 9, 2026 0

The landscape of drug development for ultra-rare diseases is undergoing a significant transformation, driven by the inherent limitations of traditional…

Read More
Pharmaceutical R&D

LEO Pharma Acquires Gene Therapy Pioneer Replay to Revolutionize Treatment for Rare Genetic Dermatological Diseases

Teuku Ryan May 2, 2026 0

In a landmark move poised to redefine the landscape of dermatological therapeutics, LEO Pharma, a global leader in medical dermatology,…

Read More
Laboratory Automation & Robotics

Rethinking Evidence Generation for Ultra-Rare Diseases

Lana Keisha May 2, 2026 0

The landscape of drug development for ultra-rare diseases is undergoing a significant transformation, driven by the U.S. Food and Drug…

Read More
Laboratory Automation & Robotics

Rethinking Evidence Generation for Ultra-Rare Diseases

Lana Keisha Apr 25, 2026 0

Developing effective treatments for ultra-rare diseases has long presented a profound paradox for the biopharmaceutical industry and regulatory bodies. While…

Read More
Pharmaceutical R&D

Terremoto Biosciences Secures $108 Million Series C to Advance Next-Generation AKT1 Inhibitors for Oncology and Rare Diseases

Teuku Ryan Apr 16, 2026 0

Terremoto Biosciences, a pioneering biotechnology company at the forefront of developing novel therapeutics targeting the PI3K/AKT pathway, announced today the…

Read More
Laboratory Automation & Robotics

Evogene, Systasy and LMU University Hospital Munich team up on AI-driven drug discovery for inflammatory diseases

Lana Keisha Apr 6, 2026 0

An ambitious new international collaboration, bolstered by a prestigious pan-European EUREKA grant, is set to revolutionize the treatment landscape for…

Read More
Pharmaceutical R&D

Canada Invests C$79 Million in Aspect Biosystems to Accelerate Development of Bioengineered Cellular Medicines for Endocrine and Metabolic Diseases

Teuku Ryan Apr 6, 2026 0

Vancouver, BC – Aspect Biosystems, a pioneering company in the field of bioengineered cellular medicines, has received a significant C$79…

Read More
Neuroscience & Brain Research

Microplastics Linked to Neurodegenerative Diseases Through Multiple Biological Pathways According to New International Study

Rifan Muazin Apr 6, 2026 0

Recent scientific investigations have unveiled a concerning correlation between the pervasive presence of microplastics in the environment and the rising…

Read More

Posts pagination

1 2 3
Clinical Labs May Gain New Edge in Early Cancer Detection with Epigenetic Instability Liquid BiopsyTWiV 1293: The enemy of your parasite is your friendMIT Engineers Develop Dual Mode Propulsion System Integrating Chemical and Electric Thrusters for Small SatellitesTheoretical Model Proposes Mini Universes Form Inside Collapsing Stars to Create Gravastars as Black Hole Alternatives
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ